YD Bio provides update on OkaiDx testing portfolio

YD Bio (YDES)provided an update to its November 5, 2025 announcement regarding U.S. access to the OkaiDx platform for post-treatment breast cancer monitoring, detailing the continued expansion of OkaiDx blood-based testing platform to pancreatic and colorectal cancer detections while presenting new clinical advances in early pancreatic cancer detection. Building on the Company’s previously announced support for the research-use-only OkaiDx breast cancer monitoring assay available through EG BioMed’s CLIA/CAP-certified laboratory, YD Bio and its affiliate have broadened clinical service availability of the OkaiDx platform in the United States. The Company now offers blood-based testing services for pancreatic and colorectal cancer detection across 44 states through EG BioMed’s accredited laboratory in Washington. Access is supported by a nationwide telehealth physician network that provides virtual consultations, test authorization, and ongoing patient support, together with an at-home blood collection partner that streamlines sample collection and logistics for patients and research collaborators.